# Psychological Assessment of Illness Denial in Medical Settings: A Critical Review

**Authors:** Danilo Carrozzino, Sara Gostoli

PMC · DOI: 10.1002/cpp.70240 · Clinical Psychology & Psychotherapy · 2026-02-16

## TL;DR

This paper reviews tools to assess illness denial in medical settings, highlighting their potential to detect complications and improve patient outcomes.

## Contribution

The paper is the first to systematically evaluate the clinical utility and clinimetric properties of illness denial instruments.

## Key findings

- The Acceptance and Action Diabetes Questionnaire and Denial of Illness Scale can screen for diabetes and stroke patients at risk.
- Transdiagnostic tools like the Diagnostic Criteria for Psychosomatic Research help identify maladaptive illness denial components.
- Instruments such as the Cardiac Denial of Impact Scale have significant prognostic value for life-threatening diseases.

## Abstract

This is the first critical review to assess the clinimetric properties, particularly the sensitivity (i.e., the ability to detect changes in clinical trials and yield clinical distinctions that may demarcate major prognostic and therapeutic differences), and to determine the clinical utility of instruments of illness denial in patients with medical disorders. A comprehensive search of the literature was performed on several databases. Patient‐reported outcome measures and clinician‐rated instruments of illness denial were identified and analysed. The findings indicate that the Acceptance and Action Diabetes Questionnaire and the Denial of Illness Scale can be used as screening tools to early detect diabetes and stroke patients at increased risk for clinical complications. The Diagnostic Criteria for Psychosomatic Research and the Levine Denial of Illness Scale are transdiagnostic instruments that are particularly suitable to identify the maladaptive manifestations of illness denial and its affective, behavioural and cognitive components. The Illness Denial Questionnaire, particularly the eight‐item version of the instrument, is another transdiagnostic measure that may be better suited for the evaluation of illness denial severity. The Denial of Cancer Interview can be used for a longitudinal monitoring of illness denial, whereas the Hackett–Cassem Denial Scale is recommended to assess the degree of illness denial in individuals with cardiac disorders. The use of instruments such as the Cardiac Denial of Impact Scale, the Denial Questionnaire and the Havik and Mæland Denial Scale, which were found to have considerable prognostic utility, may help patients promptly recognize and respond to life‐threatening diseases.

Instruments of illness denial may facilitate early detection of clinical complications.Assessment of illness denial may have considerable prognostic value.Certain instruments of illness denial may have transdiagnostic utility.Some of the existing instruments can be used to assess the severity of illness denial and its impact on treatment outcomes and adherence.Certain instruments can be used to assess the rate of progression of illness denial.

Instruments of illness denial may facilitate early detection of clinical complications.

Assessment of illness denial may have considerable prognostic value.

Certain instruments of illness denial may have transdiagnostic utility.

Some of the existing instruments can be used to assess the severity of illness denial and its impact on treatment outcomes and adherence.

Certain instruments can be used to assess the rate of progression of illness denial.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015), stroke (MONDO:0005098), cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** epilepsy (MESH:D004827), rheumatoid arthritis (MESH:D001172), death (MESH:D003643), Denial of Illness (MESH:D019575), hypertension (MESH:D006973), fibromyalgia (MESH:D005356), Myocardial Infarction (MESH:D009203), gastrointestinal disorders (MESH:D005767), dermatological disorders (MESH:D000168), nausea and vomiting (MESH:D020250), depression (MESH:D003866), chronic pain (MESH:D059350), renal diseases (MESH:D007674), congestive heart failure (MESH:D006333), neuropathic (MESH:D009437), appetite loss (MESH:D001068), Cardiac (MESH:D006331), vasovagal syncope (MESH:D019462), Coronary artery disease (MESH:D003324), unstable angina pectoris (MESH:D000789), cognitive and affective illness (MESH:D003072), neurodegenerative disorder (MESH:D019636), sleep disturbances (MESH:D012893), pain (MESH:D010146), acute coronary (MESH:D054058), lung cancer (MESH:D008175), psychiatric (MESH:D001523), Cancer (MESH:D009369), Diabetes (MESH:D003920), Anxiety and Depression (MESH:D001007), asthma (MESH:D001249), chronic kidney disease (MESH:D051436), AIDS (MESH:D000163), atrial arrhythmias (MESH:D001145), myocardial (MESH:D009202), acute stroke (MESH:D020521), DCPR (MESH:D011602), psoriasis (MESH:D011565)
- **Chemicals:** AADQ (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12910258/full.md

## References

110 references — full list in the complete paper: https://tomesphere.com/paper/PMC12910258/full.md

---
Source: https://tomesphere.com/paper/PMC12910258